tiprankstipranks
Trending News
More News >
WDB coco Co., Ltd. (JP:7079)
:7079
Japanese Market
Advertisement

WDB coco Co., Ltd. (7079) AI Stock Analysis

Compare
0 Followers

Top Page

JP:7079

WDB coco Co., Ltd.

(7079)

Rating:74Outperform
Price Target:
¥3,214.00
▲(15.82% Upside)
WDB coco Co., Ltd. scores highly due to its strong financial performance, characterized by robust revenue and profit growth, effective cost management, and excellent cash flow generation. The valuation is favorable, with a low P/E ratio and attractive dividend yield. However, technical indicators suggest a bearish trend, which slightly offsets the overall score.

WDB coco Co., Ltd. (7079) vs. iShares MSCI Japan ETF (EWJ)

WDB coco Co., Ltd. Business Overview & Revenue Model

Company DescriptionWDB coco Co., Ltd. provides contract services to pharmaceutical companies in Japan. The company supports the development of pharmaceuticals and medical devices with a focus on safety information management; safety information management support; clinical research support; and post-marketing safety information management operations services. It also provides support for the preparation of various translation, and QC; clinical research support; and manpower dispatch services. In addition, the company offers post-marketing surveillance (PMS) services, such as contract conclusion with medical facilities, survey explanations, receipt of survey forms, monitoring services, including conducting re-surveys, case registration center, data management, and statistical analysis. WDB coco Co., Ltd. was incorporated in 1984 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyWDB coco Co., Ltd. generates revenue through its comprehensive suite of services designed to support clinical trials and research. The company's primary revenue streams include fees charged for consulting, project management, and operational support services provided to clients in the pharmaceutical and biotechnology sectors. These services are crucial for the planning, execution, and management of clinical trials. Additionally, WDB coco Co., Ltd. may partner with other organizations or engage in collaborations that expand its service offerings and client base, further enhancing its revenue potential.

WDB coco Co., Ltd. Financial Statement Overview

Summary
WDB coco Co., Ltd. exhibits strong financial performance with impressive revenue and profit growth, supported by robust margins and effective cost management. The balance sheet is healthy, with low leverage and strong equity growth. Cash flow management is excellent, with consistent free cash flow generation. While liabilities have increased, the overall financial health remains strong.
Income Statement
88
Very Positive
WDB coco Co., Ltd. shows strong and consistent revenue growth with a notable increase from ¥2.57 billion in 2021 to ¥5.33 billion in 2025. Gross profit margin remains robust, averaging around 39% over the years, indicating effective cost management. The net profit margin has improved from 14.5% in 2021 to 17.1% in 2025, showcasing enhanced profitability. EBIT and EBITDA margins are also healthy, reflecting efficient operations. Overall, the income statement reflects strong growth and profitability.
Balance Sheet
85
Very Positive
The company's balance sheet is solid, with a low debt-to-equity ratio, indicating minimal leverage risk. Stockholders' equity has grown significantly, reflecting strong financial health. The equity ratio is high, suggesting a stable financial structure. However, the total liabilities have increased, which should be monitored. Overall, the balance sheet reflects strong financial stability and low leverage.
Cash Flow
90
Very Positive
WDB coco Co., Ltd. demonstrates strong cash flow management, with consistent growth in operating and free cash flows. The free cash flow to net income ratio is high, indicating efficient cash generation relative to earnings. The operating cash flow to net income ratio is also strong, reflecting effective cash management. The company has maintained positive free cash flow growth, underscoring its ability to generate cash beyond its operational needs.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.33B4.60B4.07B3.62B2.57B
Gross Profit2.08B1.94B1.59B1.44B903.33M
EBITDA1.37B1.31B1.12B978.74M538.66M
Net Income912.90M857.83M743.63M647.70M373.18M
Balance Sheet
Total Assets5.59B4.66B3.66B3.13B2.13B
Cash, Cash Equivalents and Short-Term Investments3.48B2.66B2.00B1.89B1.28B
Total Debt29.81M27.12M24.32M33.52M19.97M
Total Liabilities1.29B1.10B858.14M985.59M564.02M
Stockholders Equity4.30B3.56B2.80B2.15B1.57B
Cash Flow
Free Cash Flow1.10B684.97M452.26M706.12M291.89M
Operating Cash Flow1.10B772.20M517.49M747.90M293.93M
Investing Cash Flow-88.33M-91.82M-302.97M-60.48M-1.92M
Financing Cash Flow-195.83M-110.94M-101.21M-79.11M-42.87M

WDB coco Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2775.00
Price Trends
50DMA
2908.10
Negative
100DMA
3026.37
Negative
200DMA
3239.87
Negative
Market Momentum
MACD
-40.23
Positive
RSI
40.33
Neutral
STOCH
34.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7079, the sentiment is Negative. The current price of 2775 is below the 20-day moving average (MA) of 2863.60, below the 50-day MA of 2908.10, and below the 200-day MA of 3239.87, indicating a bearish trend. The MACD of -40.23 indicates Positive momentum. The RSI at 40.33 is Neutral, neither overbought nor oversold. The STOCH value of 34.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7079.

WDB coco Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
¥6.70B8.02
2.88%9.77%-10.78%
51
Neutral
$7.81B-0.22-40.01%2.29%21.48%-2.11%
€56.63M-122.54%
51
Neutral
¥7.46B
-50.88%-22.14%
44
Neutral
¥5.86B
8.12%-19.12%
41
Neutral
¥8.01B
-82.19%-106.15%
39
Underperform
¥6.77B
64.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7079
WDB coco Co., Ltd.
2,775.00
-1,186.84
-29.96%
DE:9SO
Solasia Pharma KK
0.20
-0.09
-31.03%
JP:4582
Symbio Pharmaceuticals Limited
148.00
-125.00
-45.79%
JP:4586
Medrx Co., Ltd.
111.00
1.00
0.91%
JP:4883
Modalis Therapeutics Corporation
87.00
-36.00
-29.27%
JP:4892
Cyfuse Biomedical K.K.
622.00
-14.00
-2.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025